-
Mashup Score: 32DNA methyltransferase 3A (DNMT3A) mutations and PD-(L)1 blockade efficacy in non-small cell lung cancer - 18 hour(s) ago
Despite significant improvements in overall survival with PD-(L)1 inhibition, most patients with metastatic non-small cell lung cancer (NSCLC) do not respond to immune checkpoint inhibition (ICI). Growing evidence suggests the importance of genomic alterations in modulating anti-cancer immune response and predicting ICI efficacy. However, the genomic correlates of response to ICI in NSCLC are largely unknown.
Source: www.annalsofoncology.orgCategories: General Medicine NewsTweet
-
Mashup Score: 7
With widening therapeutic indications, germline genetic testing is offered to an increasing proportion of patients with breast cancer (BC) via mainstream oncology services. However, the gene set tested varies widely from just BRCA1/BRCA2 through to ‘pan-cancer’ panels of nearly 100 genes. If a germline pathogenic variant (GPV) is detected, the BC proband and other family GPV-carriers may be offered interventions such as risk-reducing surgery and intensive surveillance over decades for the various cancers linked to that gene.
Source: www.annalsofoncology.orgCategories: General Medicine NewsTweet-
🆕 article in press: Breast cancer germline multigene panel testing in mainstream oncology based on clinical–public health utility: ESMO Precision Oncology Working Group recommendations https://t.co/bDzQ7i1rI3 https://t.co/ASVZqEC2a3
-
-
Mashup Score: 3
Patients with cancer may be at high risk of adverse outcomes from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We analyzed a cohort of patients with cancer and coronavirus 2019 (COVID-19) reported to the COVID-19 and Cancer Consortium (CCC19) to identify prognostic clinical factors, including laboratory measurements and anticancer therapies.
Source: www.annalsofoncology.orgCategories: General Medicine NewsTweet-
Association of Clinical Factors & Recent Anti-Cancer Therapy with COVID-19 Severity among Patients with Cancer: A Report from the COVID-19 and Cancer Consortium [3/18/21] @PGrivasMDPhD @arkhaki et al. @COVID19nCCC @Annals_Oncology https://t.co/WH5PPJySj6 #CCC19 #COVID19nCancer https://t.co/5tkdMEWUXx
-
-
Mashup Score: 26
Despite the intracranial efficacy of osimertinib, CNS metastases remain a major cause of morbidity and mortality in EGFR-mutant non-small cell lung cancer (NSCLC). The genomic drivers of CNS dissemination are poorly understood.
Source: www.annalsofoncology.orgCategories: General Medicine NewsTweet-
🆕 article in press: Identifying the genomic landscape of EGFR-mutant lung cancers with CNS metastases https://t.co/G09MmduSWa https://t.co/XrKeW8aNBO
-
-
Mashup Score: 7
With widening therapeutic indications, germline genetic testing is offered to an increasing proportion of patients with breast cancer (BC) via mainstream oncology services. However, the gene set tested varies widely from just BRCA1/BRCA2 through to ‘pan-cancer’ panels of nearly 100 genes. If a germline pathogenic variant (GPV) is detected, the BC proband and other family GPV-carriers may be offered interventions such as risk-reducing surgery and intensive surveillance over decades for the various cancers linked to that gene.
Source: www.annalsofoncology.orgCategories: General Medicine NewsTweet-
🆕 article in press: Breast cancer germline multigene panel testing in mainstream oncology based on clinical–public health utility: ESMO Precision Oncology Working Group recommendations https://t.co/bDzQ7i1rI3 https://t.co/ASVZqEC2a3
-
-
Mashup Score: 1
Drs Paccou et al. noted that ‘Adult patients with known lymphoma receiving chemotherapy experienced significant [bone mineral density] BMD loss at 1 year’ [1]. Their conclusions were drawn based upon 32 assessable patients with BMD better than -2.5 by T or Z scores. We find these data to be highly interesting as these results are similar to our randomized phase III clinical trial which evaluated the benefit of zoledronic acid (ZA) in the same lymphoma patient population [2]. In our trial, the patients who received ZA had stable BMD during the observation period.
Source: www.annalsofoncology.orgCategories: General Medicine NewsTweet-
BMD screening should be routine in lymphoma [2014] @mtmdphd @Lymphoma_Doc Hagemeister @Annals_Oncology https://t.co/USIjWZ7BOy #lymsm #SuppOnc #BoneHealth https://t.co/h9wflIUyKW
-
-
Mashup Score: 2
Kidney cancer (KC) lacks a coordinated pipeline for sequential neoadjuvant trials, exemplified by numerous small non-practice changing single-arm trials with variations in eligibility, endpoints and exploratory analyses(1). This is in stark contrast to other solid tumour types. For example, the International Neoadjuvant Melanoma Consortium has enabled the alignment and consistency of neoadjuvant trials with pooling of trial data and strong translational research, leading to practice-changing advances(2).
Source: www.annalsofoncology.orgCategories: General Medicine NewsTweet-
@Annals_Oncology https://t.co/CnHGDkE6kV Great initiative, let’s stop shooting in the dark. It’s time for smart, adaptive, globally coordinated neoadjuvant trials in RCC. @srossi725 @grantissimus @DrChoueiri
-
-
Mashup Score: 3
Circulating tumour DNA (ctDNA)-based detection of molecular residual disease (MRD) presents a strategy to identify patients at high risk of relapse. In this article, we profile early breast cancer patients with an ultrasensitive, whole genome sequencing (WGS)-based, tumour-informed ctDNA platform.
Source: www.annalsofoncology.orgCategories: General Medicine NewsTweet-
16/ Whole genome sequencing-powered ctDNA sequencing for breast cancer detection - @Annals_Oncology @myESMO https://t.co/7T1Q28pFp0
-
-
Mashup Score: 3
Patients with cancer may be at high risk of adverse outcomes from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We analyzed a cohort of patients with cancer and coronavirus 2019 (COVID-19) reported to the COVID-19 and Cancer Consortium (CCC19) to identify prognostic clinical factors, including laboratory measurements and anticancer therapies.
Source: www.annalsofoncology.orgCategories: General Medicine NewsTweet-
Association of Clinical Factors & Recent Anti-Cancer Therapy with COVID-19 Severity among Patients with Cancer: A Report from the COVID-19 and Cancer Consortium [3/18/21] @PGrivasMDPhD @arkhaki et al. @COVID19nCCC @Annals_Oncology https://t.co/WH5PPJySj6 #CCC19 #COVID19nCancer https://t.co/5tkdMEWUXx
-
-
Mashup Score: 1
Vaccination is an important preventive health measure to protect against symptomatic and severe COVID-19. Impaired immunity secondary to an underlying malignancy or recent receipt of antineoplastic systemic therapies can result in less robust antibody titers following vaccination and possible risk of breakthrough infection. As clinical trials evaluating COVID-19 vaccines largely excluded patients with a history of cancer and those on active immunosuppression (including chemotherapy), limited evidence is available to inform the clinical efficacy of COVID-19 vaccination across the spectrum of patients with cancer.
Source: www.annalsofoncology.orgCategories: General Medicine NewsTweet-
COVID-19 Vaccination and Breakthrough Infections in Patients with Cancer [Dec 24, 2021] @dr_aschmidt et al. @DrChoueiri @COVID19nCCC @Annals_Oncology https://t.co/ysAb5Fwqxf #COVID19 #COVID19Vaccine #CCC19 #COVID19nCancer #IDonc https://t.co/VzgXzKHPtB
-
🆕article in press: DNA methyltransferase 3A (DNMT3A) mutations and PD-(L)1 blockade efficacy in non-small cell lung cancer https://t.co/ugmKnkLYZM @DrMarkAwad @BRicciutiMD https://t.co/naCqpPF2e8